Premium
Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014
Author(s) -
Chen S. C.,
Sorrell T. C.,
Chang C. C.,
Paige E. K.,
Bryant P. A.,
Slavin M. A.
Publication year - 2014
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12597
Subject(s) - medicine , intensive care medicine , hematology , pneumocystis jirovecii , intensive care unit , candida auris , antifungal , pneumonia , dermatology
Pathogenic yeast forms are commonly associated with invasive fungal disease in the immunocompromised host, including patients with haematological malignancies and patients of haemopoietic stem cell transplants. Yeasts include the C andida spp., C ryptococcus spp., P neumocystis jirovecii and some lesser‐known pathogens. Candida species remain the most common cause of invasive yeast infections (and the most common human pathogenic fungi). These guidelines present evidence‐based recommendations for the antifungal management of established, invasive yeast infections in adult and paediatric patients in the haematology/oncology setting. Consideration is also given to the critically ill patient in intensive care units, including the neonatal intensive care unit. Evidence for ‘pre‐emptive’ or ‘diagnostic‐driven antifungal therapy’ is also discussed. For the purposes of this paper, invasive yeast diseases are categorised under the headings of invasive candidiasis, cryptococcosis and uncommon yeast infections. Specific recommendations for the management of P neumocystis jirovecii are presented in an accompanying article (see consensus guidelines by C ooley et al . appearing elsewhere in this supplement).